Related Experiment Videos
Death receptor ligands in tumors
Paola Cappello1, Francesco Novelli, Guido Forni
1Department of Clinical and Biological Sciences, University of Turin, Italy.
Abstract:
Activation of apoptosis via death receptors is a tightly regulated event, and the death pathway itself is open to interference on the part of soluble or membrane-bound decoy receptors. The aggregation state of the death-inducing ligand is a crucial factor, particularly when these molecules are used as recombinant drugs against tumors. Whether tumors are sensitive to such ligands is determined by both the net abundance of death receptors versus decoy receptors and the balance between intracellular apoptotic and antiapoptotic mechanisms. This means that in vivo elimination of tumor cells by effector arms such as T lymphocytes, natural killer cells, macrophages, and dendritic cells is dependent on both the function of activated lymphoid cells and the genetic properties of tumor cells. Death receptor ligands, however, may be a double-edged sword. When expressed on cytotoxic T lymphocytes, natural killer cells, monocytes, and dendritic cells, they induce the apoptosis of many tumor cells, whereas their expression on tumor cells induces the apoptosis of killer cells. The in vivo result is influenced by the number of infiltrating cells, their state of activation, the cytokine repertoire in the tumor microenvironment, and the ability of the tumor to produce soluble factors inhibiting their cytolytic functions.
Insights
Tumor cell apoptosis is regulated by death receptors and decoy receptors. The balance between these receptors and intracellular mechanisms determines tumor sensitivity to death ligands, impacting immune cell-mediated cancer elimination.
Area of Science:
- Immunology
- Molecular Biology
- Cancer Biology
Background:
- Apoptosis activation via death receptors is a highly regulated process.
- Decoy receptors can interfere with death receptor signaling pathways.
- The aggregation state of death-inducing ligands is critical for their therapeutic efficacy.
Purpose of the Study:
- To explore the intricate regulation of apoptosis in cancer.
- To investigate the role of death receptors and decoy receptors in tumor sensitivity.
- To understand the dual role of death receptor ligands in cancer immunity.
Main Methods:
- Analysis of death receptor and decoy receptor expression.
- Assessment of intracellular apoptotic and antiapoptotic mechanisms.
- Evaluation of immune cell-mediated tumor cell apoptosis in vitro and in vivo.
Main Results:
- Tumor sensitivity to death ligands depends on the balance of death versus decoy receptors.
- Tumor cell apoptosis is influenced by the aggregation state of death-inducing ligands.
- Death receptor ligands can induce tumor cell apoptosis but also apoptosis of immune effector cells.
Conclusions:
- The efficacy of death receptor ligands in cancer therapy is complex and context-dependent.
- Tumor genetic properties and the tumor microenvironment significantly influence immune-mediated elimination.
- Targeting death receptor pathways requires careful consideration of both tumor and host factors to optimize therapeutic outcomes.